Keyphrases
6-hydroxydopamine (6-OHDA)
100%
Dopaminergic Neurons
100%
Neuroprotective Effect
100%
Cell Signaling Pathways
100%
Neurokinin B
100%
Akt PKB
100%
Neurokinin-1 Receptor (NK1R)
100%
Parkinson's Disease
66%
In Vitro Model
66%
6-Hydroxydopamine-lesioned Rats
66%
Neuroprotection
33%
Substantia Nigra
33%
Cytotoxicity
33%
Signaling Pathway
33%
Receptor Agonist
33%
Apoptotic Pathway
33%
SH-SY5Y Cells
33%
Anti-apoptotic Proteins
33%
Striatum
33%
G Protein-coupled Receptor
33%
Substance P Receptor
33%
Basal Ganglia
33%
Substance P
33%
Pro-survival
33%
Rotation Measurement
33%
Apomorphine
33%
Survival Signaling
33%
Therapeutic Implications
33%
Serine-threonine Kinase
33%
Phosphorylated Serine
33%
Motor Deficits
33%
Neuroscience
Dopaminergic Neuron
100%
Neuroprotective Agent
100%
Cell Signaling
100%
Tachykinin Receptor
100%
Septide
100%
Neurokinin
42%
In Vivo
28%
In Vitro
28%
Treatment of Parkinson's Disease
28%
Receptor
28%
Neuroprotection
14%
Substantia nigra
14%
Oxidopamine
14%
Striatum
14%
Receptor Agonists
14%
Neurokinin 1 Receptor
14%
Basal Ganglia
14%
Cytotoxicity
14%
Apomorphine
14%
Protein Serine Threonine Kinase
14%
Substance P [6-11]
14%
Protein BAD
14%
G Protein Coupled Receptor
14%
Pharmacology, Toxicology and Pharmaceutical Science
Neuroprotective Agent
100%
Dopamine Receptor Stimulating Agent
100%
Tachykinin Receptor
100%
Septide
100%
Neurokinin
42%
Parkinson's Disease
28%
Receptor
28%
Cytotoxicity
14%
Oxidopamine
14%
Neuroprotection
14%
Apomorphine
14%
Receptor Agonist
14%
Protein Serine Threonine Kinase
14%
Neurokinin 1 Receptor
14%
G Protein Coupled Receptor
14%
Protein BAD
14%
Substance P [6-11]
14%